Ladenburg Thalmann Upgrades Alterity Therapeutics to 'Buy' with $10 Target
Ladenburg Thalmann has upgraded Alterity Therapeutics, setting a new price target of $10.
Key Points
- Ladenburg Thalmann raised its rating on Alterity Therapeutics to 'buy' with a $10 price target on June 16, 2026.
- Shares of Alterity Therapeutics traded at $4.41, with a market cap of approximately $84.3 million and a 52-week range between $2.66 and $7.00.
- Alterity Therapeutics, focused on neurodegenerative disorders, has a strong buy consensus with a mean target price of $11.00 from analysts.
On June 16, 2026, Ladenburg Thalmann raised its rating on Alterity Therapeutics Limited (NasdaqCM: ATHE) to a 'buy', setting a new price target of $10. The upgrade reflects optimism about the company's prospects in the biotechnology sector, particularly in its work on neurodegenerative disorders.
Alterity Therapeutics Stock Snapshot
Shares of NasdaqCM:ATHE traded near $4.41. Alterity Therapeutics has a market cap of about $84.3 million. Despite not being profitable, the company is actively involved in promising research, as evidenced by its negative forward P/E of -3.94. The stock's beta is -0.01, indicating low volatility compared to the market. Over the past year, the stock has ranged from $2.66 to $7.00, with a 50-day moving average of $4.28 and a 200-day moving average of $3.89.
Other Institutional Activity in Alterity Therapeutics
Among Alterity Therapeutics' institutional investors, Twin Lakes Capital Management, LLC holds 139,258 shares valued at approximately $484,618, unchanged from previous reports. HB Wealth Management, LLC also maintained its position with 58,460 shares worth around $203,441. Meanwhile, Morgan Stanley reduced its holdings by 5,300 shares, leaving it with 58,382 shares valued at $203,170. Citadel Advisors LLC increased its position by 3,266 shares, now holding 20,077 shares worth $71,474.
Analysts Set New Price Targets
On June 16, 2026, Ladenburg Thalmann assumed coverage on Alterity Therapeutics with a 'buy' rating and a $10 price target. Previously, Maxim Group maintained a 'buy' rating with a $12 target on January 30, 2025. The consensus among analysts is a 'strong buy', with a mean price target of $11.00 based on two opinions.
About Alterity Therapeutics
Alterity Therapeutics Limited, based in Melbourne, Australia, is a biotechnology company focused on developing treatments for neurodegenerative disorders such as Parkinson's disease and Multiple System Atrophy. Led by CEO Dr. David A. Stamler, the company employs a small team of nine people. Its leading drug candidate, ATH434, is in Phase II clinical trials aimed at treating Parkinson's disease and other related disorders. Alterity also operates a drug discovery platform to develop new treatments for neurological diseases.
Bottom Line
Ladenburg Thalmann's upgrade to a 'buy' rating for Alterity Therapeutics highlights the potential seen in the company's pipeline for neurodegenerative treatments. Investors track such ratings closely as they provide insights into a company's future prospects. Remember that analyst ratings are forward-looking and subject to change based on new information.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.